Sign In

Login

Password

Forgot Password ? Sign Up

COVID-19-Impfstoff (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "COVID-19-Impfstoff" in German language version.

refsWebsite
Global rank German rank
85doi.org
2nd place
3rd place
62who.int
195th place
255th place
55nih.gov
4th place
7th place
51news.google.com
59th place
461st place
34clinicaltrials.gov
5,225th place
2,461st place
33web.archive.org
1st place
1st place
33europa.eu
68th place
29th place
32redirecter.toolforge.org
33rd place
2nd place
20reuters.com
49th place
151st place
14IABotmemento.invalid
low place
low place
11spiegel.de
66th place
4th place
9rki.de
4,845th place
310th place
9pei.de
low place
3,159th place
8nature.com
234th place
203rd place
7pharmazeutische-zeitung.de
8,614th place
583rd place
7thelancet.com
2,393rd place
2,660th place
7tagesschau.de
884th place
51st place
7zdb-katalog.de
123rd place
6th place
6gov.uk
432nd place
770th place
6sueddeutsche.de
226th place
12th place
6fda.gov
447th place
751st place
5gelbe-liste.de
low place
2,430th place
5deutsche-apotheker-zeitung.de
low place
797th place
4rnd.de
2,679th place
179th place
4faz.net
240th place
13th place
4cdc.gov
218th place
968th place
4apotheke-adhoc.de
low place
1,805th place
4dw.com
204th place
145th place
3deadurl.invalid
low place
low place
3mementoweb.org
317th place
14th place
3nejm.org
2,374th place
1,391st place
3heise.de
766th place
46th place
3biontech.de
low place
low place
3swissmedic.ch
low place
low place
3aerzteblatt.de
3,043rd place
200th place
3precisionvaccinations.com
low place
low place
3astrazeneca.com
low place
low place
3statista.com
776th place
182nd place
3canada.ca
1,712th place
2,340th place
3admin.ch
279th place
42nd place
2ourworldindata.org
2,263rd place
1,625th place
2tehrantimes.com
4,540th place
9,428th place
2spektrum.de
1,960th place
130th place
2medrxiv.org
low place
low place
2derstandard.de
4,051st place
264th place
2scmp.com
362nd place
1,394th place
2uw.edu
low place
low place
2mdr.de
1,614th place
100th place
2welt.de
201st place
11th place
2covid-19vaccinetracker.org
low place
low place
2indiatimes.com
17th place
740th place
2gob.cu
low place
low place
2sld.cu
5,873rd place
low place
2abs-cbn.com
528th place
6,462nd place
2aerztezeitung.de
low place
711th place
2xinhuanet.com
309th place
1,887th place
2livemint.com
390th place
7,056th place
2n-tv.de
1,071st place
60th place
2prnewswire.com
406th place
1,055th place
2uni-tuebingen.de
8,201st place
854th place
2health.gov.il
low place
low place
2deutschlandfunk.de
1,366th place
81st place
2zdf.de
1,243rd place
75th place
2zeit.de
267th place
15th place
2bbc.com
20th place
57th place
2umweltbundesamt.de
8,161st place
558th place
2datastudio.google.com
low place
low place
2washingtonpost.com
34th place
113th place
2wto.org
3,346th place
4,975th place
2arcgis.com
2,359th place
2,662nd place
1cas.org
8,332nd place
1,213th place
1wikidata.org
43rd place
985th place
1science.org
1,160th place
2,116th place
1daebl.de
low place
low place
1tah.de
low place
6,921st place
1oe24.at
5,650th place
446th place
1doccheck.com
9,231st place
597th place
1harvard.edu
18th place
181st place
1kma-online.de
low place
5,595th place
1swr.de
1,755th place
114th place
1gavi.org
low place
low place
1nhs.uk
1,989th place
low place
1springer.com
274th place
152nd place
1stlpublicradio.org
low place
low place
1cnn.com
28th place
91st place
1cepi.net
low place
low place
1statnews.com
8,771st place
low place
1foldingathome.org
low place
low place
1planet3dnow.de
low place
low place
1scripps.edu
low place
low place
1br.de
1,260th place
73rd place
1vfa.de
low place
low place
1quarks.de
low place
3,244th place
1unicef.org
1,791st place
2,216th place
1sciencemag.org
857th place
511th place
1vizientinc.com
low place
low place
1newindianexpress.com
188th place
low place
1stemirna.com
low place
low place
1daiichisankyo.com
low place
low place
1contagionlive.com
low place
low place
1meiji.com
low place
low place
1msn.com
117th place
324th place
1ispch.cl
low place
low place
1interfax.com
low place
low place
1marketscreener.com
7,438th place
3,046th place
1pharmaceutical-technology.com
low place
low place
1chinadaily.com.cn
831st place
1,379th place
1chictr.org.cn
low place
low place
1france24.com
481st place
1,659th place
1astanatimes.com
8,381st place
low place
1biosafety.kz
low place
low place
1mb.com.ph
1,231st place
low place
1globaltimes.cn
low place
4,310th place
1trend.az
4,569th place
low place
1tasnimnews.com
995th place
low place
1dailysabah.com
2,228th place
1,754th place
1aa.com.tr
754th place
2,792nd place
1transkript.de
low place
low place
1madeinrussia.ru
low place
low place
1morgenpost.de
1,433rd place
86th place
1clinicaltrialsregister.eu
low place
low place
1pmlive.com
low place
low place
1taipeitimes.com
1,398th place
2,582nd place
1mehrnews.com
540th place
low place
1ndtv.com
138th place
2,564th place
1voanews.com
581st place
2,169th place
1mohap.gov.ae
low place
low place
1skbioscience.co.kr
low place
low place
1ivi.int
low place
low place
1orf.at
418th place
22nd place
1innovationmap.com
low place
low place
1texaschildrens.org
low place
low place
1cloverbiopharma.com
low place
low place
1cdht.gov.cn
low place
low place
1presseportal.de
1,570th place
94th place
1granma.cu
9,687th place
9,082nd place
1oncubanews.com
low place
low place
1thehindu.com
52nd place
1,705th place
1naturwissenschaften.ch
low place
low place
1t-online.de
1,069th place
59th place
1handelsblatt.com
1,065th place
65th place
1stuttgarter-nachrichten.de
3,266th place
226th place
1merkur.de
1,773rd place
111th place
1theconversation.com
928th place
2,002nd place
1euronews.com
612th place
686th place
1bundesregierung.de
5,817th place
506th place
1srf.ch
1,487th place
95th place
1nzz.ch
687th place
41st place
1tga.gov.au
3,984th place
low place
1zyduscadila.com
low place
low place
1nypost.com
208th place
373rd place
1bio.org
low place
low place
1curevac.com
low place
low place
1bioindustry.org
low place
low place
1isrctn.com
low place
low place
1inovio.com
low place
low place
1thejakartapost.com
1,142nd place
3,612th place
1nali-impfen.de
low place
low place
1tagblatt.de
low place
1,278th place
1timesofisrael.com
571st place
949th place
1clinicaltrialsarena.com
low place
low place
1emergency-live.com
low place
low place
1medicalxpress.com
8,255th place
low place
1zusammengegencorona.de
low place
low place
1schwaebische.de
7,689th place
553rd place
1rtl.de
1,285th place
77th place
1pitch-study.org
low place
low place
1smh.com.au
132nd place
414th place
1webmd.com
1,169th place
8,742nd place
1jewishpress.com
low place
low place
1ynetnews.com
1,870th place
2,271st place
1covid-datascience.com
low place
low place
1wikipedia.org
low place
low place
1salzburg.gv.at
low place
1,202nd place
1uni-koeln.de
2,455th place
501st place
1lto.de
8,512th place
537th place
1gesundheitswirtschaft.at
low place
low place
1euractiv.de
low place
1,738th place
1politico.eu
1,347th place
1,747th place
1pfizer.com
low place
low place
1aha.org
low place
low place
1health.govt.nz
low place
low place
1as-coa.org
low place
low place
1hindustantimes.com
71st place
1,990th place
1japantimes.co.jp
389th place
884th place
1focustaiwan.tw
3,164th place
6,573rd place
1galencentre.org
low place
low place
1koreatimes.co.kr
536th place
1,037th place
1pna.gov.ph
4,074th place
low place
1filipinotimes.net
low place
low place
1inquirer.net
437th place
5,221st place
1atlas-mag.net
low place
low place
1businessinsider.de
7,631st place
602nd place
1wired.com
193rd place
559th place
1siegfried.ch
low place
low place
1badische-zeitung.de
2,399th place
168th place
1med-depot.at
low place
low place
1sciencenews.org
3,410th place
5,745th place
1dpdhl.com
low place
2,911th place
1springerprofessional.de
low place
1,132nd place
1unodc.org
2,494th place
1,686th place
1interpol.int
5,023rd place
8,668th place
1abfallmanager-medizin.de
low place
7,163rd place
1leopoldina.org
low place
804th place
1tu-braunschweig.de
low place
1,582nd place
1precisionnanomedicine.com
low place
low place
1sky.com
431st place
1,377th place
1worldbank.org
231st place
103rd place
1argentina.gob.ar
3,900th place
low place
1health.gov.au
low place
8,135th place
1healthalert.gov.bh
low place
low place
1globo.com
62nd place
900th place
1minsal.cl
low place
low place
1impfdashboard.de
low place
low place
1terviseamet.ee
low place
low place
1thl.fi
low place
low place
1gouvernement.fr
7,439th place
9,046th place
1covidtracker.fr
low place
low place
1healthygibraltar.org
low place
low place
1data.gov.gr
low place
low place
1mohfw.gov.in
low place
low place
1kemkes.go.id
low place
low place
1geohive.ie
low place
low place
1covid.is
low place
low place
1governo.it
4,359th place
4,009th place
1gov.je
8,465th place
low place
1shinyapps.io
low place
low place
1moph.gov.qa
low place
low place
1minsalud.gov.co
low place
low place
1lrv.lt
low place
low place
1public.lu
2,674th place
1,111th place
1gov.mt
3,673rd place
2,309th place
1covid19.govt.nz
low place
low place
1government.nl
low place
low place
1ct.tr
low place
low place
1fhi.no
low place
low place
1gesundheitsministerium.gv.at
low place
low place
1ncoc.gov.pk
low place
low place
1covid19.gov.ph
low place
low place
1sns.gov.pt
low place
low place
1datelazi.ro
low place
low place
1gogov.ru
low place
low place
1iss.sm
low place
low place
1folkhalsomyndigheten.se
low place
low place
1moh.gov.sg
low place
low place
1gov.sk
9,182nd place
low place
1powerbi.com
low place
low place
1mscbs.gob.es
low place
low place
1saglik.gov.tr
low place
low place
1uruguaysevacuna.gub.uy
low place
low place
1ncema.gov.ae
low place
low place
1data.gov.uk
low place
low place

IABotmemento.invalid

aa.com.tr

abfallmanager-medizin.de

abs-cbn.com

news.abs-cbn.com

admin.ch

bag.admin.ch

covid19.admin.ch

aerzteblatt.de

aerztezeitung.de

aha.org

apotheke-adhoc.de

apotheke-adhoc.de

m.apotheke-adhoc.de

arcgis.com

experience.arcgis.com

rcb-gis.maps.arcgis.com

argentina.gob.ar

as-coa.org

astanatimes.com

astrazeneca.com

atlas-mag.net

badische-zeitung.de

bbc.com

bio.org

bioindustry.org

biontech.de

investors.biontech.de

biosafety.kz

br.de

bundesregierung.de

businessinsider.de

canada.ca

canada.ca

covid-vaccine.canada.ca

cas.org

commonchemistry.cas.org

cdc.gov

cdc.gov

covid.cdc.gov

cdht.gov.cn

cepi.net

chictr.org.cn

chinadaily.com.cn

clinicaltrials.gov

clinicaltrialsarena.com

clinicaltrialsregister.eu

cloverbiopharma.com

ir.cloverbiopharma.com

cnn.com

contagionlive.com

covid-19vaccinetracker.org

covid-datascience.com

covid.is

covid19.gov.ph

covid19.govt.nz

covidtracker.fr

ct.tr

asi.saglik.gov.ct.tr

curevac.com

daebl.de

daiichisankyo.com

dailysabah.com

data.gov.gr

data.gov.uk

coronavirus.data.gov.uk

datastudio.google.com

datelazi.ro

deadurl.invalid

  • The Lancet Respiratory Medicine. 2024; Heart. 2024. Zitiert aus Deutsches Ärzteblatt. Jahrgang 121, Heft 7, 5. April 2024, S. B 414.@1@2Vorlage:Toter Link/daebl.de (Seite nicht mehr abrufbar, festgestellt im Oktober 2024. Suche in Webarchiven)
  • Nach erster Covid-19-Erkrankung schwebt Patient mit Südafrika-Mutante in Lebensgefahr. In: tah.de. 12. Februar 2021, ehemals im Original (nicht mehr online verfügbar); abgerufen am 13. Februar 2021.@1@2Vorlage:Toter Link/www.tah.de (Seite nicht mehr abrufbar. Suche in Webarchiven)
  • Meredith McMorrow (internes CDC-Dokument): Ungeschwärztes CDC-Dokument im Original: Improving communications around vaccine breakthrough and vaccine effectiveness. (PDF) In: Washington Post, Echtheit bestätigt durch CDC (Reuters). 29. Juli 2021, ehemals im Original (nicht mehr online verfügbar); abgerufen am 9. August 2021.@1@2Vorlage:Toter Link/context-cdn.washingtonpost.com (Seite nicht mehr abrufbar. Suche in Webarchiven)

derstandard.de

deutsche-apotheker-zeitung.de

deutschlandfunk.de

doccheck.com

doi.org

  • K. I. Notarte, J. A. Catahay, J. V. Velasco, A. Pastrana, A. T. Ver, F. C. Pangilinan, P. J. Peligro, M. Casimiro, J. J. Guerrero, M. M. Gellaco, G. Lippi, B. M. Henry, C. Fernández-de-Las-Peñas: Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. In: EClinicalMedicine. Band 53, November 2022, S. 101624, doi:10.1016/j.eclinm.2022.101624, PMID 36051247, PMC 9417563 (freier Volltext).
  • A. Mumtaz, A. A. Sheikh, A. M. Khan, S. N. Khalid, J. Khan, A. Nasrullah, S. Sagheer, A. B. Sheikh: COVID-19 Vaccine and Long COVID: A Scoping Review. In: Life. Band 12, Nummer 7, Juli 2022, S. , doi:10.3390/life12071066, PMID 35888154, PMC 9324565 (freier Volltext).
  • P. Gao, J. Liu, M. Liu: Effect of COVID-19 Vaccines on Reducing the Risk of Long COVID in the Real World: A Systematic Review and Meta-Analysis. In: International Journal of Environmental Research and Public Health. Band 19, Nummer 19, September 2022, S. , doi:10.3390/ijerph191912422, PMID 36231717, PMC 9566528 (freier Volltext).
  • W. H. Chen, U. Strych, P. J. Hotez, M. E. Bottazzi: The SARS-CoV-2 Vaccine Pipeline: an Overview. In: Current tropical medicine reports. [elektronische Veröffentlichung vor dem Druck] März 2020, doi:10.1007/s40475-020-00201-6, PMID 32219057, PMC 7094941 (freier Volltext).
  • J. Pallesen, N. Wang, K. S. Corbett, D. Wrapp, R. N. Kirchdoerfer, H. L. Turner, C. A. Cottrell, M. M. Becker, L. Wang, W. Shi, W. P. Kong, E. L. Andres, A. N. Kettenbach, M. R. Denison, J. D. Chappell, B. S. Graham, A. B. Ward, J. S. McLellan: Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. In: Proceedings of the National Academy of Sciences. Band 114, Nummer 35, 08 2017, S. E7348–E7357, doi:10.1073/pnas.1707304114, PMID 28807998, PMC 5584442 (freier Volltext).
  • D. Wrapp, N. Wang, K. S. Corbett, J. A. Goldsmith, C. L. Hsieh, O. Abiona, B. S. Graham, J. S. McLellan: Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. In: Science. Band 367, Nummer 6483, 03 2020, S. 1260–1263, doi:10.1126/science.abb2507, PMID 32075877, PMC 7164637 (freier Volltext).
  • Frances E. Lund, Troy D. Randall: Scent of a vaccine. Science, 23. Juli 2021, Jahrgang 373, Ausgabe 6553, S. 397–399, PMID 34437109, doi:10.1126/science.abg9857
  • O. J. Watson, G. Barnsley, J. Toor, A. B. Hogan, P. Winskill, A. C. Ghani: Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. In: The Lancet. Infectious diseases. Band 22, Nummer 9, September 2022, S. 1293–1302, doi:10.1016/S1473-3099(22)00320-6, PMID 35753318, PMC 9225255 (freier Volltext).
  • J. Zhang, H. Zeng, J. Gu, H. Li, L. Zheng, Q. Zou: Progress and Prospects on Vaccine Development against SARS-CoV-2. In: Vaccines. Band 8, Nummer 2, März 2020, S. , doi:10.3390/vaccines8020153, PMID 32235387.
  • E. Padron-Regalado: Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains. In: Infectious diseases and therapy. [elektronische Veröffentlichung vor dem Druck] April 2020, doi:10.1007/s40121-020-00300-x, PMID 32328406, PMC 7177048 (freier Volltext).
  • M. Bhattacharya, A. R. Sharma, P. Patra, P. Ghosh, G. Sharma, B. C. Patra, S. S. Lee, C. Chakraborty: Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach. In: Journal of medical virology. [elektronische Veröffentlichung vor dem Druck] Februar 2020, doi:10.1002/jmv.25736, PMID 32108359.
  • S. F. Ahmed, A. A. Quadeer, M. R. McKay: Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies. In: Viruses. Band 12, Nummer 3, Februar 2020, S. , doi:10.3390/v12030254, PMID 32106567.
  • A. C. Walls, Y. J. Park, M. A. Tortorici, A. Wall, A. T. McGuire, D. Veesler: Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. In: Cell. [elektronische Veröffentlichung vor dem Druck] März 2020, doi:10.1016/j.cell.2020.02.058, PMID 32155444.
  • E. Prompetchara, C. Ketloy, T. Palaga: Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. In: Asian Pacific journal of allergy and immunology. [elektronische Veröffentlichung vor dem Druck] März 2020, doi:10.12932/AP-200220-0772, PMID 32105090.
  • Y. R. Guo, Q. D. Cao u. a.: The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. In: Military Medical Research. Band 7, Nummer 1, 03 2020, S. 11, doi:10.1186/s40779-020-00240-0, PMID 32169119, PMC 7068984 (freier Volltext) (Review).
  • D. Wrapp, N. Wang, K. S. Corbett, J. A. Goldsmith, C. L. Hsieh, O. Abiona, B. S. Graham, J. S. McLellan: Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. In: Science. Band 367, Nummer 6483, März 2020, S. 1260–1263, doi:10.1126/science.abb2507, PMID 32075877.
  • D. S. Khoury, D. Cromer, A. Reynaldi, T. E. Schlub, A. K. Wheatley, J. A. Juno, K. Subbarao, S. J. Kent, J. A. Triccas, M. P. Davenport: Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. In: Nature medicine. Band 27, Nummer 7, 07 2021, S. 1205–1211, doi:10.1038/s41591-021-01377-8, PMID 34002089, 17. Mai 2021.
  • P. A. Kristiansen, M. Page, V. Bernasconi, G. Mattiuzzo, P. Dull, K. Makar, S. Plotkin, I. Knezevic: WHO International Standard for anti-SARS-CoV-2 immunoglobulin. In: The Lancet. Band 397, Nummer 10282, 04 2021, S. 1347–1348, doi:10.1016/S0140-6736(21)00527-4, PMID 33770519, PMC 7987302 (freier Volltext).
  • D. G. Ahn, H. J. Shin, M. H. Kim, S. Lee, H. S. Kim, J. Myoung, B. T. Kim, S. J. Kim: Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). In: Journal of microbiology and biotechnology. Band 30, Nummer 3, März 2020, S. 313–324, doi:10.4014/jmb.2003.03011, PMID 32238757.
  • Yixuan J. Hou, Shiho Chiba u. a.: SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. In: Science, S. eabe8499, doi:10.1126/science.abe8499.
  • S. A. Madhi et al.: Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. The New England Journal of Medicine, 16. März 2021, doi:10.1056/NEJMoa2102214
  • Q. Wang, L. Zhang, K. Kuwahara, L. Li, Z. Liu, T. Li, H. Zhu, J. Liu, Y. Xu, J. Xie, H. Morioka, N. Sakaguchi, C. Qin, G. Liu: Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates. In: ACS infectious diseases. Band 2, Nummer 5, 30. März 2016, S. 361–376, doi:10.1021/acsinfecdis.6b00006, PMID 27627203, PMC 7075522 (freier Volltext).
  • S. Jiang, M. E. Bottazzi, L. Du, S. Lustigman, C. T. Tseng, E. Curti, K. Jones, B. Zhan, P. J. Hotez: Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. In: Expert review of vaccines. Band 11, Nummer 12, Dezember 2012, S. 1405–1413, doi:10.1586/erv.12.126, PMID 23252385, PMC 3586247 (freier Volltext).
  • Y. Honda-Okubo, D. Barnard, C. H. Ong, B. H. Peng, C. T. Tseng, N. Petrovsky: Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. In: Journal of Virology. Band 89, Nummer 6, März 2015, S. 2995–3007, doi:10.1128/JVI.02980-14, PMID 25520500, PMC 4337527 (freier Volltext).
  • P. Fine, K. Eames, D. L. Heymann: “Herd immunity”: a rough guide. In: Clinical Infectious Diseases. Band 52, Nummer 7, April 2011, S. 911–916, doi:10.1093/cid/cir007, PMID 21427399.
  • Roy M Anderson: Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. In: The Lancet. Band 396, Nr. 10263. Elsevier, 4. November 2020, S. 1614–1616, hier: 1615, doi:10.1016/S0140-6736(20)32318-7, PMID 33159850, PMC 7836302 (freier Volltext) – (englisch, thelancet.com [PDF; 460 kB; abgerufen am 13. Mai 2021] ε ist hier mit E, pc mit Vc angegeben. Die Formel für E entspricht genannter Formel, nur aufgelöst nach E.): “For a vaccine with 100 % efficacy that gives life-long protection, the level of herd immunity as a proportion of the population, pc, […] where R0 is the basic reproduction number. […] If the proportional vaccine efficacy, ε, is considered, the simple expression for pc becomes [1 – 1 / R0 ] / ε.”
  • M.A. Billah, M.M. Miah, M.N. Khan: Reproductive number of coronavirus: A systematic review and meta-analysis based on global level evidence. In: PLOS ONE. 15. Jahrgang, Nr. 11, 11. November 2020, S. e0242128, doi:10.1371/journal.pone.0242128, PMID 33175914, PMC 7657547 (freier Volltext), bibcode:2020PLoSO..1542128B.
  • Talha Khan Burki: Lifting of COVID-19 restrictions in the UK and the Delta variant. In: The Lancet. 12. Juli 2021, doi:10.1016/S2213-2600(21)00328-3, online. Zitat: “The reproductive number (R0) for the original strain of SARS-CoV-2 is roughly 2.5. The Alpha variant (B.1.1.7), which was previously dominant in the UK, is around 60 % more transmissible than the parental virus. The Delta variant is roughly 60 % more transmissible than the Alpha variant, which translates to an R0 of nearly 7.”
  • S. M. Bartsch, K. J. O’Shea, M. C. Ferguson, M. E. Bottazzi, P. T. Wedlock, U. Strych, J. A. McKinnell, S. S. Siegmund, S. N. Cox, P. J. Hotez, B. Y. Lee: Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention. In: American journal of preventive medicine. Band 59, Nummer 4, 10 2020, S. 493–503, doi:10.1016/j.amepre.2020.06.011, PMID 32778354, PMC 7361120 (freier Volltext).
  • David A. McAllister u. a.: Effect of vaccination on transmission of COVID-19: an observational study in healthcare workers and their households. In: medRvix – Preprint Server. 21. März 2021, doi:10.1101/2021.03.11.21253275, online.
  • Ross J. Harris, Jennifer A. Hall: Effect of Vaccination on Household Transmission of SARS-CoV-2 in England. In: Infectious diseases and therapy. 23. Juni 2021, doi:10.1056/NEJMc2107717, online
  • David W. Eyre et al.: The impact of SARS-CoV-2 vaccination on Alpha & Delta variant transmission. Preprint, geposted am 15. Oktober 2021, medRxiv 2021.09.28.21264260; doi:10.1101/2021.09.28.21264260.
  • Brechje de Gier et al.: Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), the Netherlands, August to September 2021. Eurosurveillance, Band 26, Nr. 44 (November 2021), doi:10.2807/1560-7917.ES.2021.26.44.2100977. PMID 34738514; PMC 8569927 (freier Volltext)
    Zitat: “Effectiveness of full vaccination of the index case against transmission to unvaccinated and fully vaccinated household contacts, respectively, was 63 % (95% confidence interval (CI): 46–75) and 40 % (95% CI: 20–54), in addition to the direct protection of vaccination of contacts against infection.”
  • Severe acute respiratory syndrome vaccine development: Experiences of vaccination against avian infectious bronchitis coronavirus. In: Avian Pathology. 32. Jahrgang, Nr. 6, 2003, S. 567–582, doi:10.1080/03079450310001621198, PMID 14676007.
  • A. Pratelli: High-cell-passage canine coronavirus vaccine providing sterilising immunity. In: Journal of Small Animal Practice. Band 48, Nummer 10, Oktober 2007, S. 574–578, doi:10.1111/j.1748-5827.2007.00416.x, PMID 17877547.
  • M. Hebben et. al.: Modified vaccinia virus Ankara as a vaccine against feline coronavirus: immunogenicity and efficacy. In: Journal of Feline Medicine and Surgery. Band 6, Nummer 2, April 2004, S. 111–118, doi:10.1016/j.jfms.2003.12.011, PMID 15123156.
  • Effects of a SARS-associated coronavirus vaccine in monkeys. In: The Lancet. 362. Jahrgang, Nr. 9399, 2003, S. 1895–1896, doi:10.1016/S0140-6736(03)14962-8, PMID 14667748.
  • Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/C mice. In: Vaccine. 32. Jahrgang, Nr. 45, 2014, S. 5975–5982, doi:10.1016/j.vaccine.2014.08.058, PMID 25192975.
  • Development of SARS vaccines and therapeutics is still needed. In: Future Virology. 8. Jahrgang, Nr. 1, 2013, S. 1–2, doi:10.2217/fvl.12.126.
  • M. M. Shehata, M. R. Gomaa, M. A. Ali et al.: Middle East respiratory syndrome coronavirus: a comprehensive review. Front. Med. 10, 120–136 (2016). doi:10.1007/s11684-016-0430-6
  • J. E. Martin et. al.: A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. In: Vaccine. Band 26, Nummer 50, November 2008, S. 6338–6343, doi:10.1016/j.vaccine.2008.09.026, PMID 18824060, PMC 2612543 (freier Volltext).
  • J. H. Beigel, et. al.: Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study. In: The Lancet. Infectious diseases. Band 18, Nummer 4, 04 2018, S. 410–418, doi:10.1016/S1473-3099(18)30002-1, PMID 29329957, PMC 5871563 (freier Volltext).
  • K. Modjarrad et. al.: Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. In: The Lancet. Infectious diseases. Band 19, Nummer 9, September 2019, S. 1013–1022, doi:10.1016/S1473-3099(19)30266-X, PMID 31351922.
  • J. Pang et. al.: Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review. In: Journal of clinical medicine. Band 9, Nummer 3, Februar 2020, doi:10.3390/jcm9030623, PMID 32110875.
  • T. Kramps, K. Elbers: Introduction to RNA Vaccines. In: Methods in molecular biology. Band 1499, 2017, S. 1–11, doi:10.1007/978-1-4939-6481-9_1, PMID 27987140.
  • Ugur Sahin et al.: Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. In: Nature. Band 547, Nr. 7662, Juli 2017, S. 222–226, doi:10.1038/nature23003.
  • Martin Alberer et al.: Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. In: The Lancet. Band 390, Nr. 10101, Juli 2017, S. 1511–1520, doi:10.1016/S0140-6736(17)31665-3.
  • Norbert Pardi et al.: Recent advances in mRNA vaccine technology. In: Current Opinion in Immunology. Band 65, August 2020, S. 14–20, doi:10.1016/j.coi.2020.01.008.
  • Norbert Pardi et al.: mRNA vaccines – a new era in vaccinology. In: Nature Reviews Drug Discovery. Band 17, April 2018, S. 261–279, doi:10.1038/nrd.2017.243.
  • Stanley A. Plotkin, A. Caplan: Extraordinary diseases require extraordinary solutions. In: Vaccine. Band 38, Nummer 24, 05 2020, S. 3987–3988, doi:10.1016/j.vaccine.2020.04.039, PMID 32331807, PMC 7167540 (freier Volltext).
  • N. Eyal, M. Lipsitch, P. G. Smith: Human challenge studies to accelerate coronavirus vaccine licensure. In: The Journal of Infectious Diseases. [elektronische Veröffentlichung vor dem Druck] März 2020, doi:10.1093/infdis/jiaa152, PMID 32232474, PMC 7184325 (freier Volltext).
  • G. O. Schaefer, Clarence C. Tam, Julian Savulescu, Teck Chuan Voo: Covid-19 Vaccine Development: Time to Consider Sars-Cov-2 Challenge Studies? In: SSRN Electronic Journal. , doi:10.2139/ssrn.3568981.
  • Seema K. Shah, Franklin G. Miller, Thomas C. Darton, Devan Duenas, Claudia Emerson, Holly Fernandez Lynch, Euzebiusz Jamrozik, Nancy S. Jecker, Dorcas Kamuya, Melissa Kapulu, Jonathan Kimmelman, Douglas MacKay, Matthew J. Memoli, Sean C. Murphy, Ricardo Palacios, Thomas L. Richie, Meta Roestenberg, Abha Saxena, Katherine Saylor, Michael J. Selgelid, Vina Vaswani, Annette Rid: Ethics of controlled human infection to study COVID-19. In: Science., S. eabc1076, 22. Mai 2020. doi:10.1126/science.abc1076.
  • B. Bambery, M. Selgelid, C. Weijer, J. Savulescu, A. J. Pollard: Ethical Criteria for Human Challenge Studies in Infectious Diseases. In: Public health ethics. Band 9, Nummer 1, April 2016, S. 92–103, doi:10.1093/phe/phv026, PMID 29731811, PMC 5926904 (freier Volltext).
  • E. Callaway: Should scientists infect healthy people with the coronavirus to test vaccines? In: Nature. Band 580, Nummer 7801, 2. April 2020, S. 17, doi:10.1038/d41586-020-00927-3, PMID 32218549.
  • Jon Cohen: Speed coronavirus vaccine testing by deliberately infecting volunteers? Not so fast, some scientists warn. In: Science, 31. Mai 2020. doi:10.1126/science.abc0006.
  • Emily Waltz: COVID vaccine makers brace for a variant worse than Delta. In: Nature. Band 598, Nr. 7882, 20. Oktober 2021, S. 552–553, doi:10.1038/d41586-021-02854-3 (nature.com [abgerufen am 26. November 2021]).
  • John Hodgson: The pandemic pipeline. In: Nature Biotechnology. Band 38, 20. März 2020, S. 523–532, doi:10.1038/d41587-020-00005-z, PMID 32203293 (englisch, nature.com [abgerufen am 23. März 2020]).
  • J. Sadoff, M. Le Gars u. a.: Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. In: The New England Journal of Medicine. Band 384, Nummer 19, 05 2021, S. 1824–1835, doi:10.1056/NEJMoa2034201, PMID 33440088, PMC 7821985 (freier Volltext).
  • Xiaoming Yang: Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults – A Randomized Clinical Trial. JAMA, 26. Mai 2021, doi:10.1001/jama.2021.8565.
  • Serhat Ünal / The CoronaVac Study Group: Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet, 8. Juli 2021, doi:10.1016/S0140-6736(21)01429-X
  • Fiona Godlee: Covid 19: Hope is being eclipsed by deep frustration. In: BMJ. , S. n171, doi:10.1136/bmj.n171.
  • Joon Young Song, Won Suk Choi, Jung Yeon Heo et al.: Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial. In: eClinicalMedicine. Band 51, 22. Juli 2022, S. 101569, doi:10.1016/j.eclinm.2022.101569, PMID 35879941, PMC 9304916 (freier Volltext).
  • Meredith Wadman: Novavax vaccine delivers 89% efficacy against COVID-19 in U.K.—but is less potent in South Africa. In: Science. 2021, doi:10.1126/science.abg8101.
  • Denis Y. Logunov, Inna V. Dolzhikova, Dmitry V. Shcheblyakov, Amir I. Tukhvatulin, Olga V. Zubkova: Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. In: The Lancet. Band 397, Nr. 10275, Februar 2021, ISSN 0140-6736, S. 671–681, doi:10.1016/s0140-6736(21)00234-8, PMID 33545094, PMC 7852454 (freier Volltext).
  • Fernando P. Polack, Stephen J. Thomas, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. In: New England Journal of Medicine. 10. Dezember 2020, ISSN 0028-4793, doi:10.1056/NEJMoa2034577, PMID 33301246, PMC 7745181 (freier Volltext).
  • Lindsey R. Baden et al.: Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. In: The New England Journal of Medicine. 30. Dezember 2020, doi:10.1056/NEJMoa2035389 (online).
  • Smriti Mallapaty: India’s DNA COVID vaccine is a world first – more are coming. In: Nature. Band 597, 2. September 2021, S. 161–162, doi:10.1038/d41586-021-02385-x (englisch, nature.com [PDF; 260 kB; abgerufen am 3. September 2021]).
  • H. H. Thorp: Underpromise, overdeliver. In: Science. Band 367, Nummer 6485, 27. März 2020, S. 1405, doi:10.1126/science.abb8492, PMID 32205459.
  • F. Amanat, F. Krammer: SARS-CoV-2 Vaccines: Status Report. In: Immunity. Band 52, Nummer 4, 6. April 2020, S. 583–589, doi:10.1016/j.immuni.2020.03.007, PMID 32259480, PMC 7136867 (freier Volltext).
  • T. Thanh Le, Z. Andreadakis, A. Kumar, R. Gómez Román, S. Tollefsen, M. Saville, S. Mayhew: The COVID-19 vaccine development landscape. In: Nature reviews. Drug discovery. [elektronische Veröffentlichung vor dem Druck] April 2020, doi:10.1038/d41573-020-00073-5, PMID 32273591.
  • Brechje de Gier et al.: Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), the Netherlands, August to September 2021. Eurosurveillance, Band 26, Nr. 44 (November 2021), doi:10.2807/1560-7917.ES.2021.26.44.2100977.
  • Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19–Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance — Nine States, June–August 2021. In: cdc.gov. 10. September 2021, abgerufen am 13. September 2021: „CDC used the VISION Network to examine medical encounters (32,867) from 187 hospitals […] Among fully vaccinated patients, the proportion […] among hospitalizations […] were Pfizer-BioNTech, 55.3% […]; Moderna, 38.8% […]; and Janssen, 6.0% […] VE against COVID-19 hospitalization was 86 % (95% CI = 82%–89%). VE was significantly lower among adults aged ≥75 years (76%) than among those aged 18–74 years (89%)“ doi:10.15585/mmwr.mm7037e2
  • Michela Antonelli et al.: Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. (PDF) In: Infectious Diseases, Online First. thelancet.com, 1. September 2021, S. 8, 10 f., abgerufen am 10. September 2021 (englisch, s. a. Figure 3: Disease severity and duration factors in SARS-CoV-2-infected vaccinated versus unvaccinated participants, mit zugehörigen Daten in Supplementary Material, S. 7, Supplementary Table 11, 14. Einzelsymptome dazu s. Supplementary Table 13, 15): „Almost all symptoms were reported less frequently in infected vaccinated individuals than in infected unvaccinated individuals, and vaccinated participants were more likely to be completely asymptomatic, especially if they were 60 years or older. […] This prospective, community-based, nested, case-control study used data from UK-based […] Data from 1 531 762 app users reporting an RT-PCR or LFAT test […] We found that the odds of having symptoms for 28 days or more after post-vaccination infection were approximately halved by having two vaccine doses. This result suggests that the risk of long COVID is reduced in individuals who have received double vaccination, when additionally considering the already documented reduced risk of infection overall. […] Our data suggest that the risk of post-vaccination SARS-CoV-2 infection is reduced in older age groups. […] Fully vaccinated individuals with COVID-19, especially if they were 60 years or older, were more likely to be completely asymptomatic than were unvaccinated controls. […] Supplementary Table 11. Univariate analysis assessing the probability of asymptomatic infection, severe disease (>5 reported symptoms during acute infection), hospitalisation and duration of symptoms ≥28 days in app participants following first and second vaccination, adjusted by age, BMI, and sex. […] Younger adults (18–59 years); Older adults (60+ years) / Hospitalisation […] D2 […] 0,57 […]; 0,15 / symptoms lasting ≥28 days […] D2 […] 0,37 […]; 0,56 […] D2=After second dose“ doi:10.1016/S1473-3099(21)00460-6
  • Y. Du, L. Chen, Y. Shi: Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: A systematic review. In: Human vaccines & immunotherapeutics. Band 18, Nummer 5, November 2022, S. 2062983, doi:10.1080/21645515.2022.2062983, PMID 35499517.
  • S. Chenchula, P. Karunakaran, S. Sharma, M. Chavan: Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review. In: Journal of medical virology. Band 94, Nummer 7, Juli 2022, S. 2969–2976, doi:10.1002/jmv.27697, PMID 35246846, PMC 9088621 (freier Volltext) (Review).
  • A. Renn, Y. Fu, X. Hu, M.D. Hall, A. Simeonov: Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2. Trends in Pharmacological Sciences, 31. Juli 2020 [elektronische Veröffentlichung vor dem Druck] doi:10.1016/j.tips.2020.07.004
  • A. Casadevall, L. A. Pirofski: The convalescent sera option for containing COVID-19. In: The Journal of clinical investigation. [elektronische Veröffentlichung vor dem Druck] März 2020, doi:10.1172/JCI138003, PMID 32167489.
  • Ewen Callaway: Mix-and-match COVID vaccines trigger potent immune response. In: Nature. Band 593, Nr. 7860, 19. Mai 2021, ISSN 0028-0836, S. 491–491, doi:10.1038/d41586-021-01359-3.
  • Meagan E. Deming, Kirsten E. Lyke: A ‘mix and match’ approach to SARS-CoV-2 vaccination. In: Nature Medicine. 26. Juli 2021, ISSN 1546-170X, S. 1–2, doi:10.1038/s41591-021-01463-x (nature.com [abgerufen am 16. August 2021]).
  • Joana Barros-Martins, Swantje I. Hammerschmidt, Anne Cossmann, Ivan Odak, Metodi V. Stankov: Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. In: Nature Medicine. 14. Juli 2021, ISSN 1546-170X, S. 1–5, doi:10.1038/s41591-021-01449-9 (nature.com [abgerufen am 16. August 2021]).
  • Tina Schmidt, Verena Klemis, David Schub, Janine Mihm, Franziska Hielscher: Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. In: Nature Medicine. 26. Juli 2021, ISSN 1546-170X, S. 1–6, doi:10.1038/s41591-021-01464-w (nature.com [abgerufen am 16. August 2021]).
  • Lisa Müller, Marcel Andrée, Wiebke Moskorz, Ingo Drexler, Lara Walotka: Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination. Infectious Diseases (except HIV/AIDS), 5. März 2021, doi:10.1101/2021.03.03.21251066 (medrxiv.org [abgerufen am 16. August 2021]).
  • T. Brosh-Nissimov, E. Orenbuch-Harroch, M. Chowers, M. Elbaz, L. Nesher, M. Stein, Y. Maor, R. Cohen, K. Hussein, M. Weinberger, O. Zimhony, B. Chazan, R. Najjar, H. Zayyad, G. Rahav, Y. Wiener-Well: BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. In: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. [elektronische Veröffentlichung vor dem Druck] Juli 2021, doi:10.1016/j.cmi.2021.06.036, PMID 34245907, PMC 8261136 (freier Volltext).
  • Patrick Hunziker: Personalized-dose Covid-19 vaccination in a wave of virus Variants of Concern: Trading individual efficacy for societal benefit. In: Precision Nanomedicine. 24. Juli 2021, ISSN 2639-9431, doi:10.33218/001c.26101 (precisionnanomedicine.com [abgerufen am 16. August 2021]).

dpdhl.com

dw.com

dw.com

p.dw.com

emergency-live.com

euractiv.de

euronews.com

de.euronews.com

europa.eu

ema.europa.eu

ec.europa.eu

global-response.europa.eu

eca.europa.eu

faz.net

fda.gov

fhi.no

filipinotimes.net

focustaiwan.tw

foldingathome.org

folkhalsomyndigheten.se

france24.com

galencentre.org

codeblue.galencentre.org

gavi.org

gelbe-liste.de

geohive.ie

covid-19.geohive.ie

gesundheitsministerium.gv.at

info.gesundheitsministerium.gv.at

gesundheitswirtschaft.at

globaltimes.cn

globo.com

especiais.g1.globo.com

gob.cu

salud.msp.gob.cu

gogov.ru

gouvernement.fr

gov.je

gov.mt

deputyprimeminister.gov.mt

gov.sk

korona.gov.sk

gov.uk

government.nl

coronadashboard.government.nl

governo.it

granma.cu

de.granma.cu

handelsblatt.com

harvard.edu

ui.adsabs.harvard.edu

health.gov.au

health.gov.il

datadashboard.health.gov.il

health.govt.nz

healthalert.gov.bh

healthygibraltar.org

heise.de

hindustantimes.com

impfdashboard.de

indiatimes.com

timesofindia.indiatimes.com

innovationmap.com

houston.innovationmap.com

inovio.com

ir.inovio.com

inquirer.net

newsinfo.inquirer.net

interfax.com

interpol.int

ispch.cl

isrctn.com

iss.sm

vaccinocovid.iss.sm

ivi.int

japantimes.co.jp

jewishpress.com

kemkes.go.id

vaksin.kemkes.go.id

kma-online.de

koreatimes.co.kr

leopoldina.org

livemint.com

lrv.lt

koronastop.lrv.lt

lto.de

madeinrussia.ru

marketscreener.com

mb.com.ph

mdr.de

med-depot.at

medicalxpress.com

medrxiv.org

  • David A. McAllister u. a.: Effect of vaccination on transmission of COVID-19: an observational study in healthcare workers and their households. In: medRvix – Preprint Server. 21. März 2021, doi:10.1101/2021.03.11.21253275, online.
  • Lisa Müller, Marcel Andrée, Wiebke Moskorz, Ingo Drexler, Lara Walotka: Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination. Infectious Diseases (except HIV/AIDS), 5. März 2021, doi:10.1101/2021.03.03.21251066 (medrxiv.org [abgerufen am 16. August 2021]).

mehrnews.com

en.mehrnews.com

meiji.com

mementoweb.org

timetravel.mementoweb.org

  • The Lancet Respiratory Medicine. 2024; Heart. 2024. Zitiert aus Deutsches Ärzteblatt. Jahrgang 121, Heft 7, 5. April 2024, S. B 414.@1@2Vorlage:Toter Link/daebl.de (Seite nicht mehr abrufbar, festgestellt im Oktober 2024. Suche in Webarchiven)
  • Nach erster Covid-19-Erkrankung schwebt Patient mit Südafrika-Mutante in Lebensgefahr. In: tah.de. 12. Februar 2021, ehemals im Original (nicht mehr online verfügbar); abgerufen am 13. Februar 2021.@1@2Vorlage:Toter Link/www.tah.de (Seite nicht mehr abrufbar. Suche in Webarchiven)
  • Meredith McMorrow (internes CDC-Dokument): Ungeschwärztes CDC-Dokument im Original: Improving communications around vaccine breakthrough and vaccine effectiveness. (PDF) In: Washington Post, Echtheit bestätigt durch CDC (Reuters). 29. Juli 2021, ehemals im Original (nicht mehr online verfügbar); abgerufen am 9. August 2021.@1@2Vorlage:Toter Link/context-cdn.washingtonpost.com (Seite nicht mehr abrufbar. Suche in Webarchiven)

merkur.de

minsal.cl

deis.minsal.cl

minsalud.gov.co

moh.gov.sg

mohap.gov.ae

mohfw.gov.in

moph.gov.qa

covid19.moph.gov.qa

morgenpost.de

mscbs.gob.es

msn.com

n-tv.de

nali-impfen.de

nature.com

naturwissenschaften.ch

ncema.gov.ae

covid19.ncema.gov.ae

ncoc.gov.pk

ndtv.com

nejm.org

newindianexpress.com

news.google.com

nhs.uk

nih.gov

ncbi.nlm.nih.gov

  • K. I. Notarte, J. A. Catahay, J. V. Velasco, A. Pastrana, A. T. Ver, F. C. Pangilinan, P. J. Peligro, M. Casimiro, J. J. Guerrero, M. M. Gellaco, G. Lippi, B. M. Henry, C. Fernández-de-Las-Peñas: Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. In: EClinicalMedicine. Band 53, November 2022, S. 101624, doi:10.1016/j.eclinm.2022.101624, PMID 36051247, PMC 9417563 (freier Volltext).
  • A. Mumtaz, A. A. Sheikh, A. M. Khan, S. N. Khalid, J. Khan, A. Nasrullah, S. Sagheer, A. B. Sheikh: COVID-19 Vaccine and Long COVID: A Scoping Review. In: Life. Band 12, Nummer 7, Juli 2022, S. , doi:10.3390/life12071066, PMID 35888154, PMC 9324565 (freier Volltext).
  • P. Gao, J. Liu, M. Liu: Effect of COVID-19 Vaccines on Reducing the Risk of Long COVID in the Real World: A Systematic Review and Meta-Analysis. In: International Journal of Environmental Research and Public Health. Band 19, Nummer 19, September 2022, S. , doi:10.3390/ijerph191912422, PMID 36231717, PMC 9566528 (freier Volltext).
  • W. H. Chen, U. Strych, P. J. Hotez, M. E. Bottazzi: The SARS-CoV-2 Vaccine Pipeline: an Overview. In: Current tropical medicine reports. [elektronische Veröffentlichung vor dem Druck] März 2020, doi:10.1007/s40475-020-00201-6, PMID 32219057, PMC 7094941 (freier Volltext).
  • J. Pallesen, N. Wang, K. S. Corbett, D. Wrapp, R. N. Kirchdoerfer, H. L. Turner, C. A. Cottrell, M. M. Becker, L. Wang, W. Shi, W. P. Kong, E. L. Andres, A. N. Kettenbach, M. R. Denison, J. D. Chappell, B. S. Graham, A. B. Ward, J. S. McLellan: Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. In: Proceedings of the National Academy of Sciences. Band 114, Nummer 35, 08 2017, S. E7348–E7357, doi:10.1073/pnas.1707304114, PMID 28807998, PMC 5584442 (freier Volltext).
  • D. Wrapp, N. Wang, K. S. Corbett, J. A. Goldsmith, C. L. Hsieh, O. Abiona, B. S. Graham, J. S. McLellan: Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. In: Science. Band 367, Nummer 6483, 03 2020, S. 1260–1263, doi:10.1126/science.abb2507, PMID 32075877, PMC 7164637 (freier Volltext).
  • Frances E. Lund, Troy D. Randall: Scent of a vaccine. Science, 23. Juli 2021, Jahrgang 373, Ausgabe 6553, S. 397–399, PMID 34437109, doi:10.1126/science.abg9857
  • O. J. Watson, G. Barnsley, J. Toor, A. B. Hogan, P. Winskill, A. C. Ghani: Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. In: The Lancet. Infectious diseases. Band 22, Nummer 9, September 2022, S. 1293–1302, doi:10.1016/S1473-3099(22)00320-6, PMID 35753318, PMC 9225255 (freier Volltext).
  • J. Zhang, H. Zeng, J. Gu, H. Li, L. Zheng, Q. Zou: Progress and Prospects on Vaccine Development against SARS-CoV-2. In: Vaccines. Band 8, Nummer 2, März 2020, S. , doi:10.3390/vaccines8020153, PMID 32235387.
  • E. Padron-Regalado: Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains. In: Infectious diseases and therapy. [elektronische Veröffentlichung vor dem Druck] April 2020, doi:10.1007/s40121-020-00300-x, PMID 32328406, PMC 7177048 (freier Volltext).
  • M. Bhattacharya, A. R. Sharma, P. Patra, P. Ghosh, G. Sharma, B. C. Patra, S. S. Lee, C. Chakraborty: Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach. In: Journal of medical virology. [elektronische Veröffentlichung vor dem Druck] Februar 2020, doi:10.1002/jmv.25736, PMID 32108359.
  • S. F. Ahmed, A. A. Quadeer, M. R. McKay: Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies. In: Viruses. Band 12, Nummer 3, Februar 2020, S. , doi:10.3390/v12030254, PMID 32106567.
  • A. C. Walls, Y. J. Park, M. A. Tortorici, A. Wall, A. T. McGuire, D. Veesler: Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. In: Cell. [elektronische Veröffentlichung vor dem Druck] März 2020, doi:10.1016/j.cell.2020.02.058, PMID 32155444.
  • E. Prompetchara, C. Ketloy, T. Palaga: Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. In: Asian Pacific journal of allergy and immunology. [elektronische Veröffentlichung vor dem Druck] März 2020, doi:10.12932/AP-200220-0772, PMID 32105090.
  • Y. R. Guo, Q. D. Cao u. a.: The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. In: Military Medical Research. Band 7, Nummer 1, 03 2020, S. 11, doi:10.1186/s40779-020-00240-0, PMID 32169119, PMC 7068984 (freier Volltext) (Review).
  • D. Wrapp, N. Wang, K. S. Corbett, J. A. Goldsmith, C. L. Hsieh, O. Abiona, B. S. Graham, J. S. McLellan: Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. In: Science. Band 367, Nummer 6483, März 2020, S. 1260–1263, doi:10.1126/science.abb2507, PMID 32075877.
  • D. S. Khoury, D. Cromer, A. Reynaldi, T. E. Schlub, A. K. Wheatley, J. A. Juno, K. Subbarao, S. J. Kent, J. A. Triccas, M. P. Davenport: Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. In: Nature medicine. Band 27, Nummer 7, 07 2021, S. 1205–1211, doi:10.1038/s41591-021-01377-8, PMID 34002089, 17. Mai 2021.
  • P. A. Kristiansen, M. Page, V. Bernasconi, G. Mattiuzzo, P. Dull, K. Makar, S. Plotkin, I. Knezevic: WHO International Standard for anti-SARS-CoV-2 immunoglobulin. In: The Lancet. Band 397, Nummer 10282, 04 2021, S. 1347–1348, doi:10.1016/S0140-6736(21)00527-4, PMID 33770519, PMC 7987302 (freier Volltext).
  • D. G. Ahn, H. J. Shin, M. H. Kim, S. Lee, H. S. Kim, J. Myoung, B. T. Kim, S. J. Kim: Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). In: Journal of microbiology and biotechnology. Band 30, Nummer 3, März 2020, S. 313–324, doi:10.4014/jmb.2003.03011, PMID 32238757.
  • Q. Wang, L. Zhang, K. Kuwahara, L. Li, Z. Liu, T. Li, H. Zhu, J. Liu, Y. Xu, J. Xie, H. Morioka, N. Sakaguchi, C. Qin, G. Liu: Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates. In: ACS infectious diseases. Band 2, Nummer 5, 30. März 2016, S. 361–376, doi:10.1021/acsinfecdis.6b00006, PMID 27627203, PMC 7075522 (freier Volltext).
  • S. Jiang, M. E. Bottazzi, L. Du, S. Lustigman, C. T. Tseng, E. Curti, K. Jones, B. Zhan, P. J. Hotez: Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. In: Expert review of vaccines. Band 11, Nummer 12, Dezember 2012, S. 1405–1413, doi:10.1586/erv.12.126, PMID 23252385, PMC 3586247 (freier Volltext).
  • Y. Honda-Okubo, D. Barnard, C. H. Ong, B. H. Peng, C. T. Tseng, N. Petrovsky: Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. In: Journal of Virology. Band 89, Nummer 6, März 2015, S. 2995–3007, doi:10.1128/JVI.02980-14, PMID 25520500, PMC 4337527 (freier Volltext).
  • P. Fine, K. Eames, D. L. Heymann: “Herd immunity”: a rough guide. In: Clinical Infectious Diseases. Band 52, Nummer 7, April 2011, S. 911–916, doi:10.1093/cid/cir007, PMID 21427399.
  • Roy M Anderson: Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. In: The Lancet. Band 396, Nr. 10263. Elsevier, 4. November 2020, S. 1614–1616, hier: 1615, doi:10.1016/S0140-6736(20)32318-7, PMID 33159850, PMC 7836302 (freier Volltext) – (englisch, thelancet.com [PDF; 460 kB; abgerufen am 13. Mai 2021] ε ist hier mit E, pc mit Vc angegeben. Die Formel für E entspricht genannter Formel, nur aufgelöst nach E.): “For a vaccine with 100 % efficacy that gives life-long protection, the level of herd immunity as a proportion of the population, pc, […] where R0 is the basic reproduction number. […] If the proportional vaccine efficacy, ε, is considered, the simple expression for pc becomes [1 – 1 / R0 ] / ε.”
  • M.A. Billah, M.M. Miah, M.N. Khan: Reproductive number of coronavirus: A systematic review and meta-analysis based on global level evidence. In: PLOS ONE. 15. Jahrgang, Nr. 11, 11. November 2020, S. e0242128, doi:10.1371/journal.pone.0242128, PMID 33175914, PMC 7657547 (freier Volltext), bibcode:2020PLoSO..1542128B.
  • S. M. Bartsch, K. J. O’Shea, M. C. Ferguson, M. E. Bottazzi, P. T. Wedlock, U. Strych, J. A. McKinnell, S. S. Siegmund, S. N. Cox, P. J. Hotez, B. Y. Lee: Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention. In: American journal of preventive medicine. Band 59, Nummer 4, 10 2020, S. 493–503, doi:10.1016/j.amepre.2020.06.011, PMID 32778354, PMC 7361120 (freier Volltext).
  • Brechje de Gier et al.: Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), the Netherlands, August to September 2021. Eurosurveillance, Band 26, Nr. 44 (November 2021), doi:10.2807/1560-7917.ES.2021.26.44.2100977. PMID 34738514; PMC 8569927 (freier Volltext)
    Zitat: “Effectiveness of full vaccination of the index case against transmission to unvaccinated and fully vaccinated household contacts, respectively, was 63 % (95% confidence interval (CI): 46–75) and 40 % (95% CI: 20–54), in addition to the direct protection of vaccination of contacts against infection.”
  • Severe acute respiratory syndrome vaccine development: Experiences of vaccination against avian infectious bronchitis coronavirus. In: Avian Pathology. 32. Jahrgang, Nr. 6, 2003, S. 567–582, doi:10.1080/03079450310001621198, PMID 14676007.
  • A. Pratelli: High-cell-passage canine coronavirus vaccine providing sterilising immunity. In: Journal of Small Animal Practice. Band 48, Nummer 10, Oktober 2007, S. 574–578, doi:10.1111/j.1748-5827.2007.00416.x, PMID 17877547.
  • M. Hebben et. al.: Modified vaccinia virus Ankara as a vaccine against feline coronavirus: immunogenicity and efficacy. In: Journal of Feline Medicine and Surgery. Band 6, Nummer 2, April 2004, S. 111–118, doi:10.1016/j.jfms.2003.12.011, PMID 15123156.
  • Effects of a SARS-associated coronavirus vaccine in monkeys. In: The Lancet. 362. Jahrgang, Nr. 9399, 2003, S. 1895–1896, doi:10.1016/S0140-6736(03)14962-8, PMID 14667748.
  • Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/C mice. In: Vaccine. 32. Jahrgang, Nr. 45, 2014, S. 5975–5982, doi:10.1016/j.vaccine.2014.08.058, PMID 25192975.
  • J. T. Lin et. al.: Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. In: Antiviral therapy. Band 12, Nummer 7, 2007, S. 1107–1113, PMID 18018769.
  • J. E. Martin et. al.: A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. In: Vaccine. Band 26, Nummer 50, November 2008, S. 6338–6343, doi:10.1016/j.vaccine.2008.09.026, PMID 18824060, PMC 2612543 (freier Volltext).
  • J. H. Beigel, et. al.: Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study. In: The Lancet. Infectious diseases. Band 18, Nummer 4, 04 2018, S. 410–418, doi:10.1016/S1473-3099(18)30002-1, PMID 29329957, PMC 5871563 (freier Volltext).
  • K. Modjarrad et. al.: Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. In: The Lancet. Infectious diseases. Band 19, Nummer 9, September 2019, S. 1013–1022, doi:10.1016/S1473-3099(19)30266-X, PMID 31351922.
  • J. Pang et. al.: Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review. In: Journal of clinical medicine. Band 9, Nummer 3, Februar 2020, doi:10.3390/jcm9030623, PMID 32110875.
  • T. Kramps, K. Elbers: Introduction to RNA Vaccines. In: Methods in molecular biology. Band 1499, 2017, S. 1–11, doi:10.1007/978-1-4939-6481-9_1, PMID 27987140.
  • Stanley A. Plotkin, A. Caplan: Extraordinary diseases require extraordinary solutions. In: Vaccine. Band 38, Nummer 24, 05 2020, S. 3987–3988, doi:10.1016/j.vaccine.2020.04.039, PMID 32331807, PMC 7167540 (freier Volltext).
  • N. Eyal, M. Lipsitch, P. G. Smith: Human challenge studies to accelerate coronavirus vaccine licensure. In: The Journal of Infectious Diseases. [elektronische Veröffentlichung vor dem Druck] März 2020, doi:10.1093/infdis/jiaa152, PMID 32232474, PMC 7184325 (freier Volltext).
  • B. Bambery, M. Selgelid, C. Weijer, J. Savulescu, A. J. Pollard: Ethical Criteria for Human Challenge Studies in Infectious Diseases. In: Public health ethics. Band 9, Nummer 1, April 2016, S. 92–103, doi:10.1093/phe/phv026, PMID 29731811, PMC 5926904 (freier Volltext).
  • E. Callaway: Should scientists infect healthy people with the coronavirus to test vaccines? In: Nature. Band 580, Nummer 7801, 2. April 2020, S. 17, doi:10.1038/d41586-020-00927-3, PMID 32218549.
  • John Hodgson: The pandemic pipeline. In: Nature Biotechnology. Band 38, 20. März 2020, S. 523–532, doi:10.1038/d41587-020-00005-z, PMID 32203293 (englisch, nature.com [abgerufen am 23. März 2020]).
  • J. Sadoff, M. Le Gars u. a.: Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. In: The New England Journal of Medicine. Band 384, Nummer 19, 05 2021, S. 1824–1835, doi:10.1056/NEJMoa2034201, PMID 33440088, PMC 7821985 (freier Volltext).
  • Joon Young Song, Won Suk Choi, Jung Yeon Heo et al.: Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial. In: eClinicalMedicine. Band 51, 22. Juli 2022, S. 101569, doi:10.1016/j.eclinm.2022.101569, PMID 35879941, PMC 9304916 (freier Volltext).
  • Denis Y. Logunov, Inna V. Dolzhikova, Dmitry V. Shcheblyakov, Amir I. Tukhvatulin, Olga V. Zubkova: Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. In: The Lancet. Band 397, Nr. 10275, Februar 2021, ISSN 0140-6736, S. 671–681, doi:10.1016/s0140-6736(21)00234-8, PMID 33545094, PMC 7852454 (freier Volltext).
  • Fernando P. Polack, Stephen J. Thomas, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. In: New England Journal of Medicine. 10. Dezember 2020, ISSN 0028-4793, doi:10.1056/NEJMoa2034577, PMID 33301246, PMC 7745181 (freier Volltext).
  • H. H. Thorp: Underpromise, overdeliver. In: Science. Band 367, Nummer 6485, 27. März 2020, S. 1405, doi:10.1126/science.abb8492, PMID 32205459.
  • F. Amanat, F. Krammer: SARS-CoV-2 Vaccines: Status Report. In: Immunity. Band 52, Nummer 4, 6. April 2020, S. 583–589, doi:10.1016/j.immuni.2020.03.007, PMID 32259480, PMC 7136867 (freier Volltext).
  • T. Thanh Le, Z. Andreadakis, A. Kumar, R. Gómez Román, S. Tollefsen, M. Saville, S. Mayhew: The COVID-19 vaccine development landscape. In: Nature reviews. Drug discovery. [elektronische Veröffentlichung vor dem Druck] April 2020, doi:10.1038/d41573-020-00073-5, PMID 32273591.
  • Y. Du, L. Chen, Y. Shi: Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: A systematic review. In: Human vaccines & immunotherapeutics. Band 18, Nummer 5, November 2022, S. 2062983, doi:10.1080/21645515.2022.2062983, PMID 35499517.
  • S. Chenchula, P. Karunakaran, S. Sharma, M. Chavan: Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review. In: Journal of medical virology. Band 94, Nummer 7, Juli 2022, S. 2969–2976, doi:10.1002/jmv.27697, PMID 35246846, PMC 9088621 (freier Volltext) (Review).
  • A. Casadevall, L. A. Pirofski: The convalescent sera option for containing COVID-19. In: The Journal of clinical investigation. [elektronische Veröffentlichung vor dem Druck] März 2020, doi:10.1172/JCI138003, PMID 32167489.
  • T. Brosh-Nissimov, E. Orenbuch-Harroch, M. Chowers, M. Elbaz, L. Nesher, M. Stein, Y. Maor, R. Cohen, K. Hussein, M. Weinberger, O. Zimhony, B. Chazan, R. Najjar, H. Zayyad, G. Rahav, Y. Wiener-Well: BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. In: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. [elektronische Veröffentlichung vor dem Druck] Juli 2021, doi:10.1016/j.cmi.2021.06.036, PMID 34245907, PMC 8261136 (freier Volltext).

nih.gov

nypost.com

nzz.ch

oe24.at

oncubanews.com

orf.at

ourworldindata.org

  • COVID-19 vaccine doses administered per 100 people. OWID; (englisch, Letzte Aktualisierung siehe Weltkarte. Daten basieren auf offiziellen Quellen. Alle Impfdosen, inklusive Booster, werden separat gezählt. Da dieselbe Person mehr als eine Impfdosis erhalten kann, kann die Anzahl der Impfdosen je 100 Personen höher sein als 100. Alle Impfdosen werden somit einzeln gezählt, also jeweils 1. und 2. Dosis separat, zzgl. jeweils 1., 2. und 3. Booster separat etc.).
  • Saloni Dattani, Lucas Rodés-Guira: Key charts to understand the COVID-19 pandemic. In: Our World in Data. 18. November 2024, abgerufen am 27. November 2024 (englisch).

pei.de

pfizer.com

pharmaceutical-technology.com

pharmazeutische-zeitung.de

pitch-study.org

  • Sustained T cell immunity, protection and boosting using extended dosing intervals of BNT162b2 mRNA vaccine. (PDF) In: pitch-study.org. 23. Juli 2021, abgerufen am 13. September 2021: „The serologic response to one or two doses of BNT162b2 falls over time, and is higher after an extended dosing interval compared with the 3–4 week dosing interval that was tested in the licensing trials. By contrast, the T cell response is … of a marginally lower magnitude after the longer dosing interval when measured by the ELISpot assay of T cell effector function, yet shows a more developed memory cell phenotype compared with the 3–4 week dosing interval.“

planet3dnow.de

pmlive.com

pna.gov.ph

politico.eu

powerbi.com

app.powerbi.com

precisionnanomedicine.com

precisionvaccinations.com

presseportal.de

prnewswire.com

public.lu

data.public.lu

quarks.de

redirecter.toolforge.org

reuters.com

rki.de

rnd.de

rtl.de

saglik.gov.tr

covid19asi.saglik.gov.tr

salzburg.gv.at

schwaebische.de

science.org

sciencemag.org

vis.sciencemag.org

sciencenews.org

scmp.com

scripps.edu

shinyapps.io

art-bd.shinyapps.io

siegfried.ch

skbioscience.co.kr

sky.com

news.sky.com

sld.cu

rpcec.sld.cu

smh.com.au

sns.gov.pt

spektrum.de

spiegel.de

springer.com

link.springer.com

springerprofessional.de

srf.ch

statista.com

statnews.com

stemirna.com

stlpublicradio.org

news.stlpublicradio.org

stuttgarter-nachrichten.de

sueddeutsche.de

swissmedic.ch

swr.de

t-online.de

tagblatt.de

tagesschau.de

tah.de

  • Nach erster Covid-19-Erkrankung schwebt Patient mit Südafrika-Mutante in Lebensgefahr. In: tah.de. 12. Februar 2021, ehemals im Original (nicht mehr online verfügbar); abgerufen am 13. Februar 2021.@1@2Vorlage:Toter Link/www.tah.de (Seite nicht mehr abrufbar. Suche in Webarchiven)

taipeitimes.com

tasnimnews.com

tehrantimes.com

terviseamet.ee

texaschildrens.org

tga.gov.au

theconversation.com

thehindu.com

thejakartapost.com

thelancet.com

  • Roy M Anderson: Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. In: The Lancet. Band 396, Nr. 10263. Elsevier, 4. November 2020, S. 1614–1616, hier: 1615, doi:10.1016/S0140-6736(20)32318-7, PMID 33159850, PMC 7836302 (freier Volltext) – (englisch, thelancet.com [PDF; 460 kB; abgerufen am 13. Mai 2021] ε ist hier mit E, pc mit Vc angegeben. Die Formel für E entspricht genannter Formel, nur aufgelöst nach E.): “For a vaccine with 100 % efficacy that gives life-long protection, the level of herd immunity as a proportion of the population, pc, […] where R0 is the basic reproduction number. […] If the proportional vaccine efficacy, ε, is considered, the simple expression for pc becomes [1 – 1 / R0 ] / ε.”
  • Talha Khan Burki: Lifting of COVID-19 restrictions in the UK and the Delta variant. In: The Lancet. 12. Juli 2021, doi:10.1016/S2213-2600(21)00328-3, online. Zitat: “The reproductive number (R0) for the original strain of SARS-CoV-2 is roughly 2.5. The Alpha variant (B.1.1.7), which was previously dominant in the UK, is around 60 % more transmissible than the parental virus. The Delta variant is roughly 60 % more transmissible than the Alpha variant, which translates to an R0 of nearly 7.”
  • Roy M. Anderson u.a.: Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. In: The Lancet, Band 396, Ausgabe 10263, 21. November 2020.
  • Yanjun Zhang, Gang Zeng, Hongxing Pan, Changgui Li, Yaling Hu, Kai Chu et al.: Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet, 17. November 2020, abgerufen am 26. April 2021.
  • Michela Antonelli et al.: Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. (PDF) In: Infectious Diseases, Online First. thelancet.com, 1. September 2021, S. 8, 10 f., abgerufen am 10. September 2021 (englisch, s. a. Figure 3: Disease severity and duration factors in SARS-CoV-2-infected vaccinated versus unvaccinated participants, mit zugehörigen Daten in Supplementary Material, S. 7, Supplementary Table 11, 14. Einzelsymptome dazu s. Supplementary Table 13, 15): „Almost all symptoms were reported less frequently in infected vaccinated individuals than in infected unvaccinated individuals, and vaccinated participants were more likely to be completely asymptomatic, especially if they were 60 years or older. […] This prospective, community-based, nested, case-control study used data from UK-based […] Data from 1 531 762 app users reporting an RT-PCR or LFAT test […] We found that the odds of having symptoms for 28 days or more after post-vaccination infection were approximately halved by having two vaccine doses. This result suggests that the risk of long COVID is reduced in individuals who have received double vaccination, when additionally considering the already documented reduced risk of infection overall. […] Our data suggest that the risk of post-vaccination SARS-CoV-2 infection is reduced in older age groups. […] Fully vaccinated individuals with COVID-19, especially if they were 60 years or older, were more likely to be completely asymptomatic than were unvaccinated controls. […] Supplementary Table 11. Univariate analysis assessing the probability of asymptomatic infection, severe disease (>5 reported symptoms during acute infection), hospitalisation and duration of symptoms ≥28 days in app participants following first and second vaccination, adjusted by age, BMI, and sex. […] Younger adults (18–59 years); Older adults (60+ years) / Hospitalisation […] D2 […] 0,57 […]; 0,15 / symptoms lasting ≥28 days […] D2 […] 0,37 […]; 0,56 […] D2=After second dose“ doi:10.1016/S1473-3099(21)00460-6
  • R. Krause et al.: Considerations in boosting COVID-19 vaccine immune responses. In: The Lancet. 13. September 2021, abgerufen am 26. Oktober 2021 (deutschsprachige Bearbeitung unterstützt von Deepl-Übersetzer).
  • Noam Barda, Noa Dagan, Cyrille Cohen, Miguel A. Hernán, Marc Lipsitch, Isaac Kohane et al.: Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. The Lancet, 29. Oktober 2021, abgerufen am 7. November 2021.

thl.fi

timesofisrael.com

transkript.de

trend.az

en.trend.az

tu-braunschweig.de

umweltbundesamt.de

uni-koeln.de

verwaltungslehre.uni-koeln.de

uni-tuebingen.de

medizin.uni-tuebingen.de

unicef.org

unodc.org

uruguaysevacuna.gub.uy

monitor.uruguaysevacuna.gub.uy

uw.edu

ipd.uw.edu

vfa.de

vizientinc.com

voanews.com

washingtonpost.com

context-cdn.washingtonpost.com

washingtonpost.com

web.archive.org

webmd.com

welt.de

who.int

covid19.who.int

who.int

extranet.who.int

cdn.who.int

apps.who.int

wikidata.org

wikipedia.org

en.wikipedia.org

wired.com

worldbank.org

datahelpdesk.worldbank.org

  • World Bank Country and Lending Groups. In: datahelpdesk.worldbank.org. Abgerufen am 31. Dezember 2021: „For the current 2022 fiscal year, low-income economies are defined as those with a GNI per capita […] of $1,045 or less in 2020“

wto.org

docs.wto.org

wto.org

xinhuanet.com

ynetnews.com

zdb-katalog.de

  • Denis Y. Logunov, Inna V. Dolzhikova, Dmitry V. Shcheblyakov, Amir I. Tukhvatulin, Olga V. Zubkova: Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. In: The Lancet. Band 397, Nr. 10275, Februar 2021, ISSN 0140-6736, S. 671–681, doi:10.1016/s0140-6736(21)00234-8, PMID 33545094, PMC 7852454 (freier Volltext).
  • Fernando P. Polack, Stephen J. Thomas, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. In: New England Journal of Medicine. 10. Dezember 2020, ISSN 0028-4793, doi:10.1056/NEJMoa2034577, PMID 33301246, PMC 7745181 (freier Volltext).
  • Ewen Callaway: Mix-and-match COVID vaccines trigger potent immune response. In: Nature. Band 593, Nr. 7860, 19. Mai 2021, ISSN 0028-0836, S. 491–491, doi:10.1038/d41586-021-01359-3.
  • Meagan E. Deming, Kirsten E. Lyke: A ‘mix and match’ approach to SARS-CoV-2 vaccination. In: Nature Medicine. 26. Juli 2021, ISSN 1546-170X, S. 1–2, doi:10.1038/s41591-021-01463-x (nature.com [abgerufen am 16. August 2021]).
  • Joana Barros-Martins, Swantje I. Hammerschmidt, Anne Cossmann, Ivan Odak, Metodi V. Stankov: Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. In: Nature Medicine. 14. Juli 2021, ISSN 1546-170X, S. 1–5, doi:10.1038/s41591-021-01449-9 (nature.com [abgerufen am 16. August 2021]).
  • Tina Schmidt, Verena Klemis, David Schub, Janine Mihm, Franziska Hielscher: Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. In: Nature Medicine. 26. Juli 2021, ISSN 1546-170X, S. 1–6, doi:10.1038/s41591-021-01464-w (nature.com [abgerufen am 16. August 2021]).
  • Patrick Hunziker: Personalized-dose Covid-19 vaccination in a wave of virus Variants of Concern: Trading individual efficacy for societal benefit. In: Precision Nanomedicine. 24. Juli 2021, ISSN 2639-9431, doi:10.33218/001c.26101 (precisionnanomedicine.com [abgerufen am 16. August 2021]).

zdf.de

zeit.de

zusammengegencorona.de

zyduscadila.com